Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.
Identifieur interne : 002E33 ( PubMed/Curation ); précédent : 002E32; suivant : 002E34Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.
Auteurs : Marc J. Mentis [États-Unis] ; Dominique Delalot ; Hassan Naqvi ; Mark F. Gordon ; Mark Gudesblatt ; Christine Edwards ; Luke Donatelli ; Vijay Dhawan ; David EidelbergSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Analysis of Variance, Biomechanical Phenomena, Brain (drug effects), Brain (pathology), Brain (radionuclide imaging), Cholinesterase Inhibitors (therapeutic use), Double-Blind Method, Female, Humans, Indans (therapeutic use), Male, Movement (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (pathology), Parkinson Disease (physiopathology), Piperidines (therapeutic use), Positron-Emission Tomography (methods).
- MESH :
- chemical , therapeutic use : Cholinesterase Inhibitors, Indans, Piperidines.
- drug effects : Brain, Movement.
- drug therapy : Parkinson Disease.
- methods : Positron-Emission Tomography.
- pathology : Brain, Parkinson Disease.
- physiopathology : Parkinson Disease.
- radionuclide imaging : Brain.
- Analysis of Variance, Biomechanical Phenomena, Double-Blind Method, Female, Humans, Male.
Abstract
Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor function. A small literature suggests AChE therapy has little effect on clinical motor evaluation; however, no study has made objective motor kinematic measures or evaluated brain function. We hypothesized that even if clinical examination was normal in PD patients on dopamine therapy, (1) sensitive kinematic measures would be abnormal during AChE therapy or (2) normal kinematic measures would be maintained by compensatory brain activation. We carried out a randomized, double-blind, placebo-controlled trial of 8 weeks donepezil (10 mg/day) in 17 PD subjects. Subjects carried out a computerized motor task during a positron emission tomography (PET) scan before starting the drug and again after 8 weeks of donepezil or placebo. Kinematic measures of motor function and PET scans were analyzed to compare the effects of donepezil and placebo. Neither placebo nor donepezil altered motor kinematic measures. Furthermore, movement integrity while on donepezil was maintained without compensatory brain activity. Donepezil 10 mg/day can be given for nonmotor symptoms in PD without adverse motor effects or compensatory brain activity.
DOI: 10.1002/mds.20706
PubMed: 16228997
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002E33
Links to Exploration step
pubmed:16228997Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.</title><author><name sortKey="Mentis, Marc J" sort="Mentis, Marc J" uniqKey="Mentis M" first="Marc J" last="Mentis">Marc J. Mentis</name><affiliation wicri:level="1"><nlm:affiliation>Center for Neurosciences, North Shore-LIJ Health System, New Hyde Park, NY 11030, USA. mentis@nshs.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Neurosciences, North Shore-LIJ Health System, New Hyde Park, NY 11030</wicri:regionArea></affiliation></author><author><name sortKey="Delalot, Dominique" sort="Delalot, Dominique" uniqKey="Delalot D" first="Dominique" last="Delalot">Dominique Delalot</name></author><author><name sortKey="Naqvi, Hassan" sort="Naqvi, Hassan" uniqKey="Naqvi H" first="Hassan" last="Naqvi">Hassan Naqvi</name></author><author><name sortKey="Gordon, Mark F" sort="Gordon, Mark F" uniqKey="Gordon M" first="Mark F" last="Gordon">Mark F. Gordon</name></author><author><name sortKey="Gudesblatt, Mark" sort="Gudesblatt, Mark" uniqKey="Gudesblatt M" first="Mark" last="Gudesblatt">Mark Gudesblatt</name></author><author><name sortKey="Edwards, Christine" sort="Edwards, Christine" uniqKey="Edwards C" first="Christine" last="Edwards">Christine Edwards</name></author><author><name sortKey="Donatelli, Luke" sort="Donatelli, Luke" uniqKey="Donatelli L" first="Luke" last="Donatelli">Luke Donatelli</name></author><author><name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20706</idno><idno type="RBID">pubmed:16228997</idno><idno type="pmid">16228997</idno><idno type="wicri:Area/PubMed/Corpus">002E33</idno><idno type="wicri:Area/PubMed/Curation">002E33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.</title><author><name sortKey="Mentis, Marc J" sort="Mentis, Marc J" uniqKey="Mentis M" first="Marc J" last="Mentis">Marc J. Mentis</name><affiliation wicri:level="1"><nlm:affiliation>Center for Neurosciences, North Shore-LIJ Health System, New Hyde Park, NY 11030, USA. mentis@nshs.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Neurosciences, North Shore-LIJ Health System, New Hyde Park, NY 11030</wicri:regionArea></affiliation></author><author><name sortKey="Delalot, Dominique" sort="Delalot, Dominique" uniqKey="Delalot D" first="Dominique" last="Delalot">Dominique Delalot</name></author><author><name sortKey="Naqvi, Hassan" sort="Naqvi, Hassan" uniqKey="Naqvi H" first="Hassan" last="Naqvi">Hassan Naqvi</name></author><author><name sortKey="Gordon, Mark F" sort="Gordon, Mark F" uniqKey="Gordon M" first="Mark F" last="Gordon">Mark F. Gordon</name></author><author><name sortKey="Gudesblatt, Mark" sort="Gudesblatt, Mark" uniqKey="Gudesblatt M" first="Mark" last="Gudesblatt">Mark Gudesblatt</name></author><author><name sortKey="Edwards, Christine" sort="Edwards, Christine" uniqKey="Edwards C" first="Christine" last="Edwards">Christine Edwards</name></author><author><name sortKey="Donatelli, Luke" sort="Donatelli, Luke" uniqKey="Donatelli L" first="Luke" last="Donatelli">Luke Donatelli</name></author><author><name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Biomechanical Phenomena</term><term>Brain (drug effects)</term><term>Brain (pathology)</term><term>Brain (radionuclide imaging)</term><term>Cholinesterase Inhibitors (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Indans (therapeutic use)</term><term>Male</term><term>Movement (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (physiopathology)</term><term>Piperidines (therapeutic use)</term><term>Positron-Emission Tomography (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cholinesterase Inhibitors</term><term>Indans</term><term>Piperidines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term><term>Movement</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Positron-Emission Tomography</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Biomechanical Phenomena</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor function. A small literature suggests AChE therapy has little effect on clinical motor evaluation; however, no study has made objective motor kinematic measures or evaluated brain function. We hypothesized that even if clinical examination was normal in PD patients on dopamine therapy, (1) sensitive kinematic measures would be abnormal during AChE therapy or (2) normal kinematic measures would be maintained by compensatory brain activation. We carried out a randomized, double-blind, placebo-controlled trial of 8 weeks donepezil (10 mg/day) in 17 PD subjects. Subjects carried out a computerized motor task during a positron emission tomography (PET) scan before starting the drug and again after 8 weeks of donepezil or placebo. Kinematic measures of motor function and PET scans were analyzed to compare the effects of donepezil and placebo. Neither placebo nor donepezil altered motor kinematic measures. Furthermore, movement integrity while on donepezil was maintained without compensatory brain activity. Donepezil 10 mg/day can be given for nonmotor symptoms in PD without adverse motor effects or compensatory brain activity.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16228997</PMID><DateCreated><Year>2006</Year><Month>04</Month><Day>17</Day></DateCreated><DateCompleted><Year>2006</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>549-55</MedlinePgn></Pagination><Abstract><AbstractText>Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor function. A small literature suggests AChE therapy has little effect on clinical motor evaluation; however, no study has made objective motor kinematic measures or evaluated brain function. We hypothesized that even if clinical examination was normal in PD patients on dopamine therapy, (1) sensitive kinematic measures would be abnormal during AChE therapy or (2) normal kinematic measures would be maintained by compensatory brain activation. We carried out a randomized, double-blind, placebo-controlled trial of 8 weeks donepezil (10 mg/day) in 17 PD subjects. Subjects carried out a computerized motor task during a positron emission tomography (PET) scan before starting the drug and again after 8 weeks of donepezil or placebo. Kinematic measures of motor function and PET scans were analyzed to compare the effects of donepezil and placebo. Neither placebo nor donepezil altered motor kinematic measures. Furthermore, movement integrity while on donepezil was maintained without compensatory brain activity. Donepezil 10 mg/day can be given for nonmotor symptoms in PD without adverse motor effects or compensatory brain activity.</AbstractText><CopyrightInformation>Copyright 2005 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mentis</LastName><ForeName>Marc J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Center for Neurosciences, North Shore-LIJ Health System, New Hyde Park, NY 11030, USA. mentis@nshs.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delalot</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Naqvi</LastName><ForeName>Hassan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Mark F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Gudesblatt</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Donatelli</LastName><ForeName>Luke</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dhawan</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Eidelberg</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 NS002101</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 NS002101-06</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS K24 02101</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS02204</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="C076946">donepezil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001696">Biomechanical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002800">Cholinesterase Inhibitors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007189">Indans</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009068">Movement</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010880">Piperidines</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS57774</OtherID><OtherID Source="NLM">PMC4457276</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20706</ArticleId><ArticleId IdType="pubmed">16228997</ArticleId><ArticleId IdType="pmc">PMC4457276</ArticleId><ArticleId IdType="mid">NIHMS57774</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002E33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16228997
|texte= Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16228997" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |